TGF-beta pathway polymorphisms and colon cancer risk

TGF-β途径多态性与结肠癌风险

基本信息

批准号：
7350209
负责人：
Boris Pasche
金额：
$ 12.65万
依托单位：
NORTHWESTERN UNIVERSITY AT CHICAGO
依托单位国家：
美国
项目类别：
财政年份：
2006
资助国家：
美国
起止时间：
2006-02-24 至 2008-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7350209
关键词：
Address Affect Alanine Alleles Amino Acids Animal Model Area Aspirin Binding Breast Cancer Family Case-Control Studies Cell surface Code Colon Colon Carcinoma Colorectal Colorectal Cancer Complex Data Defect Disease Disease Association Doctor of Philosophy Dose Environmental Exposure Epithelial Cells Family-Based Registry Foundations Frequencies GCG gene Gene Frequency Genes Genetic Genetic Polymorphism Genotype Genus Cola Glucagon Growth Growth Inhibitors Haplotypes Heterozygote Homozygote Human In Vitro Incidence Individual Inherited Intervention Trial Laboratories Lead Leucine Ligands Malignant Neoplasms Malignant neoplasm of ovary Mediating Medical Meta-Analysis Microsatellite Instability Morbidity - disease rate Non-Steroidal Anti-Inflammatory Agents Pathogenesis Pathway interactions Patients Pattern Penetrance Positioning Attribute Predisposition Principal Investigator Proline Registries Research Research Personnel Resources Risk Siblings Signal Pathway Signal Transduction TGFB1 gene TGFBR1 gene TGFBR2 gene Testing Transforming Growth Factor beta Triplet Multiple Birth Variant Work cancer diagnosis cancer risk cancer type carcinogenesis case control cell growth design extracellular gene interaction genetic epidemiology in vivo interest mortality neoplasm registry programs receptor receptor binding tumor

项目摘要

We have previously identified TGFBR1*6A, a common variant of the TGFBR1 gene, and shown that it transmits TGF-a growth inhibitory signals less effectively than TGFBR1. Our recent meta-analyses show that TGFBR1*6A carriers have a significantly increased risk of colon, breast and ovarian cancer as compared with non-carriers. Overall, cancer risk is increased by 19% among heterozygotes and 70% among homozygotes, a pattern indicative of an allelic dosing effect. We have also shown that TGFBR1*6A may contribute to hereditary colorectal cancer. More than one in eight healthy individuals and one in six patients with cancer is a TGFBR1*6A carrier, which establishes TGFBR1*6A as the first high-frequency low-penetrance candidate tumor susceptibility allele. In contrast, increased TGF-a circulating levels have been associated with a decreased cancer risk in animal models. A common Leucine to Proline substitution at the 10th amino acid position variant within the human TGF- a1 (TGFB1) gene results in higher in vitro extracellular TGFB1 secretion. Carriers of the TGFB1*CC genotype have higher in vivo TGFB1 circulating levels than carriers of the TGFB1*TT genotype. TGFBR1 and TGFB1 variants my have opposite or synergistic effects on colorectal cancer risk. Our central hypothesis is that a combined assessment of the two functionally-relevant TGF- a pathway signaling variants will predict colorectal cancer risk more accurately than each variant alone. The NCI-sponsored familial colorectal cancer registry is an ideal resource in which to test this hypothesis. Using a sibling-matched case-control design we will genotype a total of 4,208 full sibling case-control pairs and First: assess the association between TGFBR1*6A and colorectal cancer. Second: assess the association between TGFB1 and colorectal cancer and perform haplotype analysis of the TGFB1 gene; Third: analyze gene-gene interactions between TGFBR1 and TGFB1. This will explore the relationships between the two functional TGF-a pathway polymorphisms and colorectal risk and determine whether TGF- a signaling, as predicted by these two variants, is associated with colorectal cancer risk; and, Fourth: investigate the relationship between TGF-a pathway polymorphisms and tumor microsatellite instability.

我们先前已经鉴定出TGFBR1*6A是TGFBR1基因的常见变体，并表明它的传输TGF-A生长抑制信号的有效性比TGFBR1有效。我们最近的荟萃分析表明，与非携带者相比，TGFBR1*6A携带者患结肠，乳腺癌和卵巢癌的风险显着增加。总体而言，杂合子中的癌症风险增加了19％，纯合子中的风险增加了70％，这种模式表明了等位基因剂量作用。我们还表明，TGFBR1*6A可能导致遗传性结直肠癌。 TGFBR1*6A携带者是八分之一的健康个体和六分之一的癌症患者，该携带者将TGFBR1*6A建立为第一个高频低频率候选肿瘤易感性等位基因。相比之下，TGF-A循环水平的提高与动物模型的癌症风险降低有关。在人TGF-A1（TGFB1）基因中第10个氨基酸位置变体中脯氨酸取代的常见亮氨酸导致体外细胞外TGFB1分泌。 TGFB1*CC基因型的载体在体内TGFB1循环水平高于TGFB1*TT基因型的载体。我的TGFBR1和TGFB1变体对结直肠癌的风险有相反或协同作用。我们的中心假设是，对两个与功能相关的TGF- A途径信号变异的组合评估将比单独的每个变体更准确地预测结直肠癌的风险。 NCI赞助的家族性大肠癌注册中心是检验该假设的理想资源。使用兄弟姐妹匹配的病例对照设计，我们将共同基因型4,208个完整的兄弟姐妹病例对照对，首先：评估TGFBR1*6A与结直肠癌之间的关联。第二：评估TGFB1与大肠癌之间的关联，并对TGFB1基因进行单倍型分析；第三：分析TGFBR1和TGFB1之间的基因基因相互作用。这将探讨两个功能性TGF-A途径多态性和结直肠风险之间的关系，并确定这两个变体所预测的TGF- A信号是否与大肠癌风险有关；，第四：研究TGF-A途径多态性与肿瘤微卫星不稳定性之间的关系。